John Bradley Sorenson Sells 16,351 Shares of Boston Scientific Co. (NYSE:BSX) Stock

Boston Scientific Co. (NYSE:BSXGet Free Report) EVP John Bradley Sorenson sold 16,351 shares of Boston Scientific stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $69.30, for a total value of $1,133,124.30. Following the completion of the transaction, the executive vice president now owns 50,638 shares in the company, valued at $3,509,213.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Boston Scientific Stock Performance

Boston Scientific stock opened at $68.16 on Thursday. The stock’s 50-day moving average is $65.98 and its 200-day moving average is $58.57. The company has a market cap of $100.19 billion, a price-to-earnings ratio of 63.70, a price-to-earnings-growth ratio of 2.39 and a beta of 0.78. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $68.92.

Boston Scientific (NYSE:BSXGet Free Report) last posted its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The business had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. During the same quarter last year, the firm earned $0.45 earnings per share. Equities analysts anticipate that Boston Scientific Co. will post 2.25 earnings per share for the current year.

Institutional Investors Weigh In On Boston Scientific

Large investors have recently modified their holdings of the stock. Bruce G. Allen Investments LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $28,000. Sachetta LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $32,000. Frazier Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $32,000. Jones Financial Companies Lllp grew its stake in shares of Boston Scientific by 53.0% in the fourth quarter. Jones Financial Companies Lllp now owns 557 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 193 shares in the last quarter. Finally, Sunbelt Securities Inc. acquired a new stake in shares of Boston Scientific in the first quarter valued at about $32,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the topic of several analyst reports. TD Cowen lifted their target price on Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a research note on Thursday, March 7th. Needham & Company LLC lifted their target price on Boston Scientific from $60.00 to $71.00 and gave the company a “buy” rating in a research note on Thursday, February 1st. Mizuho upgraded Boston Scientific from a “neutral” rating to a “buy” rating and lifted their price target for the company from $65.00 to $80.00 in a research note on Thursday, February 1st. BTIG Research restated a “buy” rating and issued a $64.00 price target on shares of Boston Scientific in a research note on Friday, December 29th. Finally, Wells Fargo & Company lifted their price target on Boston Scientific from $70.00 to $72.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Two investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average price target of $67.59.

Check Out Our Latest Analysis on BSX

Boston Scientific Company Profile

(Get Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Recommended Stories

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.